BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 32132242)

  • 1. An EBNA3A-Mutated Epstein-Barr Virus Retains the Capacity for Lymphomagenesis in a Cord Blood-Humanized Mouse Model.
    Romero-Masters JC; Ohashi M; Djavadian R; Eichelberg MR; Hayes M; Zumwalde NA; Bristol JA; Nelson SE; Ma S; Ranheim EA; Gumperz JE; Johannsen EC; Kenney SC
    J Virol; 2020 May; 94(10):. PubMed ID: 32132242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An EBNA3C-deleted Epstein-Barr virus (EBV) mutant causes B-cell lymphomas with delayed onset in a cord blood-humanized mouse model.
    Romero-Masters JC; Ohashi M; Djavadian R; Eichelberg MR; Hayes M; Bristol JA; Ma S; Ranheim EA; Gumperz J; Johannsen EC; Kenney SC
    PLoS Pathog; 2018 Aug; 14(8):e1007221. PubMed ID: 30125329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EBNA2-deleted Epstein-Barr virus (EBV) isolate, P3HR1, causes Hodgkin-like lymphomas and diffuse large B cell lymphomas with type II and Wp-restricted latency types in humanized mice.
    Li C; Romero-Masters JC; Huebner S; Ohashi M; Hayes M; Bristol JA; Nelson SE; Eichelberg MR; Van Sciver N; Ranheim EA; Scott RS; Johannsen EC; Kenney SC
    PLoS Pathog; 2020 Jun; 16(6):e1008590. PubMed ID: 32542010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Latent Membrane Protein 1 (LMP1) and LMP2A Collaborate To Promote Epstein-Barr Virus-Induced B Cell Lymphomas in a Cord Blood-Humanized Mouse Model but Are Not Essential.
    Ma SD; Tsai MH; Romero-Masters JC; Ranheim EA; Huebner SM; Bristol JA; Delecluse HJ; Kenney SC
    J Virol; 2017 Apr; 91(7):. PubMed ID: 28077657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epstein-Barr Virus Type 2 Infects T Cells and Induces B Cell Lymphomagenesis in Humanized Mice.
    Coleman CB; Lang J; Sweet LA; Smith NA; Freed BM; Pan Z; Haverkos B; Pelanda R; Rochford R
    J Virol; 2018 Nov; 92(21):. PubMed ID: 30089703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Latent Epstein-Barr virus infection collaborates with Myc over-expression in normal human B cells to induce Burkitt-like Lymphomas in mice.
    Bristol JA; Nelson SE; Ohashi M; Casco A; Hayes M; Ranheim EA; Pawelski AS; Singh DR; Hodson DJ; Johannsen EC; Kenney SC
    PLoS Pathog; 2024 Apr; 20(4):e1012132. PubMed ID: 38620028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epstein-Barr Virus Nuclear Antigen 3 (EBNA3) Proteins Regulate EBNA2 Binding to Distinct RBPJ Genomic Sites.
    Wang A; Welch R; Zhao B; Ta T; Keleş S; Johannsen E
    J Virol; 2015 Dec; 90(6):2906-19. PubMed ID: 26719268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional interplay of Epstein-Barr virus oncoproteins in a mouse model of B cell lymphomagenesis.
    Sommermann T; Yasuda T; Ronen J; Wirtz T; Weber T; Sack U; Caeser R; Zhang J; Li X; Chu VT; Jauch A; Unger K; Hodson DJ; Akalin A; Rajewsky K
    Proc Natl Acad Sci U S A; 2020 Jun; 117(25):14421-14432. PubMed ID: 32522871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Epstein-Barr Virus (EBV) mutant with enhanced BZLF1 expression causes lymphomas with abortive lytic EBV infection in a humanized mouse model.
    Ma SD; Yu X; Mertz JE; Gumperz JE; Reinheim E; Zhou Y; Tang W; Burlingham WJ; Gulley ML; Kenney SC
    J Virol; 2012 Aug; 86(15):7976-87. PubMed ID: 22623780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Knockout of Epstein-Barr virus BPLF1 retards B-cell transformation and lymphoma formation in humanized mice.
    Whitehurst CB; Li G; Montgomery SA; Montgomery ND; Su L; Pagano JS
    mBio; 2015 Oct; 6(5):e01574-15. PubMed ID: 26489865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The BHLF1 Locus of Epstein-Barr Virus Contributes to Viral Latency and B-Cell Immortalization.
    Yetming KD; Lupey-Green LN; Biryukov S; Hughes DJ; Marendy EM; Miranda JL; Sample JT
    J Virol; 2020 Aug; 94(17):. PubMed ID: 32581094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First Days in the Life of Naive Human B Lymphocytes Infected with Epstein-Barr Virus.
    Pich D; Mrozek-Gorska P; Bouvet M; Sugimoto A; Akidil E; Grundhoff A; Hamperl S; Ling PD; Hammerschmidt W
    mBio; 2019 Sep; 10(5):. PubMed ID: 31530670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epstein-Barr virus nuclear antigen 3A partially coincides with EBNA3C genome-wide and is tethered to DNA through BATF complexes.
    Schmidt SC; Jiang S; Zhou H; Willox B; Holthaus AM; Kharchenko PV; Johannsen EC; Kieff E; Zhao B
    Proc Natl Acad Sci U S A; 2015 Jan; 112(2):554-9. PubMed ID: 25540416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RNA Sequencing Analyses of Gene Expression during Epstein-Barr Virus Infection of Primary B Lymphocytes.
    Wang C; Li D; Zhang L; Jiang S; Liang J; Narita Y; Hou I; Zhong Q; Zheng Z; Xiao H; Gewurz BE; Teng M; Zhao B
    J Virol; 2019 Jul; 93(13):. PubMed ID: 31019051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epstein-Barr Virus (EBV) Latent Protein EBNA3A Directly Targets and Silences the
    Bazot Q; Paschos K; Allday MJ
    J Virol; 2018 Apr; 92(7):. PubMed ID: 29367247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LMP1-deficient Epstein-Barr virus mutant requires T cells for lymphomagenesis.
    Ma SD; Xu X; Plowshay J; Ranheim EA; Burlingham WJ; Jensen JL; Asimakopoulos F; Tang W; Gulley ML; Cesarman E; Gumperz JE; Kenney SC
    J Clin Invest; 2015 Jan; 125(1):304-15. PubMed ID: 25485679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancer Control of MicroRNA miR-155 Expression in Epstein-Barr Virus-Infected B Cells.
    Wood CD; Carvell T; Gunnell A; Ojeniyi OO; Osborne C; West MJ
    J Virol; 2018 Oct; 92(19):. PubMed ID: 30021904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EBV epigenetically suppresses the B cell-to-plasma cell differentiation pathway while establishing long-term latency.
    Styles CT; Bazot Q; Parker GA; White RE; Paschos K; Allday MJ
    PLoS Biol; 2017 Aug; 15(8):e2001992. PubMed ID: 28771465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EBV persistence without its EBNA3A and 3C oncogenes in vivo.
    Murer A; McHugh D; Caduff N; Kalchschmidt J; Barros M; Zbinden A; Capaul R; Niedobitek G; Allday M; Chijioke O; Münz C
    PLoS Pathog; 2018 Apr; 14(4):e1007039. PubMed ID: 29709016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EBNA2 and Its Coactivator EBNA-LP.
    Kempkes B; Ling PD
    Curr Top Microbiol Immunol; 2015; 391():35-59. PubMed ID: 26428371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.